Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA

Intra-Cellular Therapies (NASDAQ:ITCI) skyrockets 86% in premarket trading after the FDA approves its Caplyta (lumateperone) for the treatment of schizophrenia in adults.

ITCI expects Caplyta’s commercial launch in late Q1 2020.

Previously: Intra-Cellular up 10% ahead of presentation of lumateperone data (Dec. 10)

https://seekingalpha.com/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda